Compare Summit Therapeutics Inc (SMMT) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? Summit Therapeutics Inc trades at $14.65 (market cap $10.48B), while Vanguard Total International Stock Index Fund ETF trades at $84.5. The key difference: Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | VXUS | |
|---|---|---|
Market Cap | $10.48B | — |
Sector | Health | Sector/Thematic |
52-Week High | $29.32 | $87.06 |
52-Week Low | $13.05 | $68.24 |
Enterprise Value | $9.90B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
VXUS trades at $83.07, down 0.36% with a bearish technical signal from moving averages. The ETF provides diversified international exposure across 8,700+ stocks in developed and emerging markets. Recent institutional buying includes Greenwood Gearhart increasing its position by 45.8% in Q1 2026 (SEC filing, July 20, 2026). Technical indicators show neutral oscillators with support at $82 and resistance at $84.
VXUS offers cost-effective international diversification at a 0.05% expense ratio, trading at a discount to US equities. Risks include global economic sensitivity and currency fluctuations. Analyst sentiment is mixed with some caution due to inflation concerns, but long-term value exists for investors seeking non-US exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
